A Phase IA/IB Study Evaluating TAS-116 in Patients With Advanced Solid Tumors

Trial Profile

A Phase IA/IB Study Evaluating TAS-116 in Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs TAS 116 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Taiho Oncology; Taiho Pharmaceutical
  • Most Recent Events

    • 02 Jun 2017 Parts of this study will be expanded to the US with an amended study protocol, as reported in an abstract presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 02 Jun 2017 Interim results (n=52) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 15 Nov 2016 Planned End Date changed from 31 Dec 2016 to 31 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top